Edwards Lifesciences Corporation
EW
Pozycja w akcjach
#476
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Cena akcji
$88.24
Kapitalizacja rynkowa
$50.86B
Zmiana (1 dzień)
1.08%
Zmiana (1 rok)
17.19%
Kraj
US
Handel Edwards Lifesciences Corporation (EW)
Kategoria
Healthcare
Przychody dla Edwards Lifesciences Corporation (EW)
Przychody w Jun 2026 TTM: $6.51B
Według najnowszych raportów finansowych Edwards Lifesciences Corporation, obecny przychód firmy (TTM) wynosi $6.51B. W roku 2024 firma osiągnęła przychód w wysokości $5.44B wzrost w porównaniu do przychodu z roku 2023, który wynosił $5.01B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Edwards Lifesciences Corporation od 2000 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $6.51B | 7.33% |
| 2025 | $6.07B | 11.55% |
| 2024 | $5.44B | 8.57% |
| 2023 | $5.01B | -6.92% |
| 2022 | $5.38B | 2.86% |
| 2021 | $5.23B | 19.29% |
| 2020 | $4.39B | 0.88% |
| 2019 | $4.35B | 16.79% |
| 2018 | $3.72B | 8.37% |
| 2017 | $3.44B | 15.91% |
| 2016 | $2.96B | 18.85% |
| 2015 | $2.49B | 7.35% |
| 2014 | $2.32B | 13.56% |
| 2013 | $2.05B | 7.68% |
| 2012 | $1.90B | 13.17% |
| 2011 | $1.68B | 16.01% |
| 2010 | $1.45B | 9.51% |
| 2009 | $1.32B | 6.76% |
| 2008 | $1.24B | 13.44% |
| 2007 | $1.09B | 5.22% |
| 2006 | $1.04B | 3.92% |
| 2005 | $997.90M | 7.13% |
| 2004 | $931.50M | 8.25% |
| 2003 | $860.50M | 22.23% |
| 2002 | $704.00M | 1.73% |
| 2001 | $692.00M | -13.93% |
| 2000 | $804.00M | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $46.59B | 615.34% |
US
|
|
| $35.48B | 444.88% |
IE
|
|
| $25.84B | 296.74% |
US
|
|
| $21.00B | 222.41% |
US
|
|
| - | - |
DE
|
